Article

Optherion obtains rights for newest AMD treatment

New Haven, CT-Optherion Inc., among the newest companies to attempt treatments for age-related macular degeneration (AMD), just licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on chromosome 10.

New Haven, CT-Optherion Inc., among the newest companies to attempt treatments for age-related macular degeneration (AMD), just licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on chromosome 10.

In 2005, scientists from the University of Pittsburgh published findings of a link between chromosomes 10, specifically LOC387715 and HTRA1 genes, and AMD.

If genetic tests can identify people at risk of developing AMD, then physicians can take action more aggressively and at an earlier stage with lifestyle changes and therapies, according to Optherion.

"We are optimistic that the innovative discoveries we are licensing will lead to diagnostic tests that can help change the current paradigm of AMD risk assessment and patient care," said Colin J. Foster, president and chief executive officer of Optherion.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.